Common

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Tuesday, March 28, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Apremilast, Bristol Myers Squibb, University, Civil service commission, Infection, Psoriasis, Lower respiratory tract infection, Doctor of Philosophy, BMY, Dermatology, Incidence, PSO, MD, Patient, Physician, TYK2, Common, NYSE, LTE, European Commission, Pharmaceutical industry, Deucravacitinib

The POETYK study program demonstrated a consistent safety profile in patients through three years of continuous treatment.

Key Points: 
  • The POETYK study program demonstrated a consistent safety profile in patients through three years of continuous treatment.
  • “Today’s approval is a landmark achievement as patients across Europe with moderate-to-severe plaque psoriasis will now have the opportunity to be treated with Sotyktu, the first once-daily oral option to provide significant symptom relief,” said Samit Hirawat , MD, chief medical officer, Bristol Myers Squibb.
  • Up to 90% of patients with psoriasis have psoriasis vulgaris, or plaque psoriasis, which is characterized by distinct round or oval plaques typically covered by silvery-white scales.
  • The majority of infections were non-serious and mild to moderate in severity and did not lead to the discontinuation of Sotyktu.

Tudor Gold Announces Upsized $16 Million Bought-Deal Private Placement Offering, With Participation By Mr. Eric Sprott

Retrieved on: 
Friday, March 24, 2023
Cloud, Exercise, Indian stock exchange, NOT, TSX Venture Exchange, Section 50C of the Isle of Man Income Tax Act 1970, FOR, Tax, Foreign Investment in Real Property Tax Act, Underwriting, Sale, Initial public offering, Offering, ULC, Charity, Income Tax Act, Wainwright Securities Inc. v. Wall Street Transcript Corp., Common, Security (finance), Closing

VANCOUVER, British Columbia, March 24, 2023 (GLOBE NEWSWIRE) -- Tudor Gold Corp. (TSXV: TUD) (the “Company”) is pleased to announce that, due to strong investor demand, it has entered into an amended agreement with Research Capital Corporation, as the lead underwriter and sole bookrunner (the “Lead Underwriter”), on behalf of a syndicate of underwriters, including Red Cloud Securities Inc. and Roth Canada, ULC (collectively, the “Underwriters”), to increase the size of its previously announced bought-deal, private placement offering from $10,000,000 to approximately $16,000,000 in aggregate gross proceeds to the Company (the “Offering”). Mr. Eric Sprott, through 2176423 Ontario Ltd., has indicated his intention to subscribe in the Offering.

Key Points: 
  • Mr. Eric Sprott, through 2176423 Ontario Ltd., has indicated his intention to subscribe in the Offering.
  • The Offering consists of securities of the Company (the “Offered Securities”) in a combination of:
    a) flow-through units of the Company (the “FT Units”) at a price of $1.28 per FT Unit.
  • The Offered Securities to be issued under the Offering will be offered by way of private placement in each of the provinces of Canada.
  • This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

Coreum L1 Launches, with New Smart Token Technology to Unlock Potential of DeFi

Retrieved on: 
Friday, March 24, 2023
XRP, Citadel, Lighthouse, IBC, ETF, Second wave, Ledger, Stably free module, Amber, Ecosystem, Common, Cryptocurrency, Telio

DUBAI, United Arab Emirates, March 24, 2023 (GLOBE NEWSWIRE) -- Coreum, the new enterprise-grade layer one blockchain developed by the Coreum Development Foundation, has officially launched. The low-latency, proof-of-stake blockchain supports the expansion of modular, fast, secure, and interoperable blockchain-based applications, ultimately cultivating the mass adoption of decentralized technology among enterprise-grade entities.

Key Points: 
  • Truly plug-and-play, these tokens are faster, more secure, and more reliable compared to smart contracts.
  • The release of the Coreum blockchain represents the last step of what has been a well-staged development plan, with its origin based on the Sologenic Tokenization Technology .
  • Corerum has just launched its second wave of grants, Wave 2, geared at projects that will leverage Coreum's proprietary Smart Token technology.
  • To apply for a Coreum Smart Token grant, visit https://coreum.typeform.com/wave-2 .

EQS-News: Fürstenberg Capital II GmbH: Sharing in Losses and Redemption at Reduced Book Value / No Coupon Payment in 2023

Retrieved on: 
Friday, March 24, 2023
Note, Partnership, WKN, Bis zum bitteren Ende – Die Toten Hosen Live!, Capital note, Participation, Common, Euronext Amsterdam, Capital, Issuer, ISIN, HGB, Card security code, Norddeutsche Landesbank, Der, Heute, Security (finance), Adhesive, NORD/LB

Soweit die Emittentin keine Zahlungen aus dem Beteiligungsvertrag erhält, ist die Emittentin nicht verpflichtet, Zahlungen auf die Capital Notes zu leisten.

Key Points: 
  • Soweit die Emittentin keine Zahlungen aus dem Beteiligungsvertrag erhält, ist die Emittentin nicht verpflichtet, Zahlungen auf die Capital Notes zu leisten.
  • Thus, the repayment amount payable on the Capital Notes on 30 June 2023 is expected to amount to EUR 533.63 per Capital Note.
  • 1 der Emissionsbedingungen der Capital Notes für die Rückzahlung der Capital Notes zu verwendende Rückzahlungsbetrag entspricht dem oben genannten Buchwert der stillen Einlage zum 31.
  • Juni 2023 auf die Capital Notes zu zahlende Rückzahlungsbetrag voraussichtlich EUR 533,63 je Capital Note betragen wird.

EQS-News: Fürstenberg Capital Erste GmbH: Sharing in Losses and Redemption at Reduced Book Value / No Coupon Payment in 2023

Retrieved on: 
Friday, March 24, 2023
Note, Partnership, Bis zum bitteren Ende – Die Toten Hosen Live!, Capital note, Participation, Common, Euronext Amsterdam, Capital, Issuer, ISIN, HGB, Card security code, Norddeutsche Landesbank, Der, Heute, Security (finance), Adhesive, NORD/LB

Soweit die Emittentin keine Zahlungen aus dem Beteiligungsvertrag erhält, ist die Emittentin nicht verpflichtet, Zahlungen auf die Capital Notes zu leisten.

Key Points: 
  • Soweit die Emittentin keine Zahlungen aus dem Beteiligungsvertrag erhält, ist die Emittentin nicht verpflichtet, Zahlungen auf die Capital Notes zu leisten.
  • Thus, the repayment amount payable on the Capital Notes on 30 June 2023 is expected to amount to EUR 533.63 per Capital Note.
  • 1 der Emissionsbedingungen der Capital Notes für die Rückzahlung der Capital Notes zu verwendende Rückzahlungsbetrag entspricht dem oben genannten Buchwert der stillen Einlage zum 31.
  • Juni 2023 auf die Capital Notes zu zahlende Rückzahlungsbetrag voraussichtlich EUR 533,63 je Capital Note betragen wird.

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

Retrieved on: 
Friday, March 24, 2023
Exercise, Computershare, Certificate of incorporation, Therapy, Mass, Special, CUSIP, Common, Security (finance)

Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023

Key Points: 
  • Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023
    BOSTON, Mass - March 24, 2023 — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post split share for every 35 pre-split shares.
  • The CUSIP number for Allarity’s common stock following the reverse stock split will be 016744203.
  • As a result of the reverse stock split, at the Effective Time, every 35 shares of Allarity’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share.
  • The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 34,294,582 shares to approximately approximately 979,846 shares.

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
SDMA, MTAP, Incentive program, WSE, Patient, PIM, MM, EIB, Leukemia, Therapy, Warsaw Stock Exchange, Service, MTA, Culture, DLBCL, Multiple myeloma, Research, WT, Hematology, Growth, European Investment Bank, Phase, Common, BioNTech, WIG20, AACR, BofA Securities, Cancer, IC50, 100 Best Companies to Work For, Acute myeloid leukemia, American Association for Cancer Research, Publication, Germinal center B-cell like diffuse large B-cell lymphoma, SWIG, HL, Update, PRMT5, Partnership, Exelixis, AML, Pharmaceutical industry, Vaccine, Medical imaging

“2022 was a highly productive year for Ryvu as we made significant strides across our clinical programs, collaboration activity, and in strengthening our balance sheet,” said Pawel Przewiezlikowski, co-founder, largest shareholder and CEO of Ryvu Therapeutics.

Key Points: 
  • “2022 was a highly productive year for Ryvu as we made significant strides across our clinical programs, collaboration activity, and in strengthening our balance sheet,” said Pawel Przewiezlikowski, co-founder, largest shareholder and CEO of Ryvu Therapeutics.
  • Among the investors participating in this offering were also company insiders (including the CEO) with a total investment of over $5M in the offering.
  • Cash Position – On December 31, 2022, Ryvu Therapeutics held $23.2M in cash and cash equivalents, compared to $20.5M at the end of 2021.
  • Net Loss Attributable to Common Shareholders – Net loss attributable to common shareholders excluding the non-cash cost of valuation of the Incentive Program was $1.4M, for the fourth quarter of 2022, compared to the $2.6M, for the fourth quarter of 2021.

TAL ALERT: Bragar Eagel & Squire, P.C. is Investigating TAL Education Group on Behalf of TAL Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 24, 2023
Legal, Professional Services, P.C, ADR, Alpha, TAL Education Group, TAL, Prosperity, Telephone, American depositary receipt, Jeanne Eagels (film), Mathematics, Education, News, NYSE, Common

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TAL Education Group (“TAL” or the “Company”) (NYSE: TAL) on behalf of TAL stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TAL Education Group (“TAL” or the “Company”) (NYSE: TAL) on behalf of TAL stockholders.
  • Our investigation concerns whether TAL has violated the federal securities laws and/or engaged in other unlawful business practices.
  • The article further reported that "TAL subsidiary Xueersi restarted courses that run counter to conventions put in place by Xi Jinping's Common Prosperity drive.
  • Specifically, courses were restarted in subjects like mathematics and English under the guise of permitted tutoring outside of core subjects.

Goldshore Resources Announces Brokered Private Placement of up to $5 Million

Retrieved on: 
Thursday, March 23, 2023
Unit, Indian stock exchange, NOT, TSX Venture Exchange, Income Tax Act 1967, FOR, Canada Revenue Agency, Person, Tax, OTC Markets Group, Foreign Investment in Real Property Tax Act, Sale, Initial public offering, WIRE, Agent, Offering, NEWS, Income Tax Act, News, Common, Security (finance), Bank, Paternoster Valley

VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Goldshore Resources Inc. (TSXV: GSHR / OTC Markets: GSHRF / FWB: 8X00) (“Goldshore” or the “Company”), is pleased to announce that it has entered into an agreement with Research Capital Corporation and Eventus Capital Corp., as co-lead agents and joint bookrunners (the “Lead Agents”), on their own behalf and on behalf of a syndicate of agents to be formed (together with the Lead Agents, the “Agents”), in connection with a brokered private placement of the following securities (the “Offered Securities”) for aggregate gross proceeds of up to $5,000,000 (the “Offering”):

Key Points: 
  • The Agents’ Option may be exercised in whole or in part at any time prior to the Closing Date of the Offering.
  • The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S.
  • Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S.
  • Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Tudor Gold Announces $10 Million Bought-Deal Private Placement Offering

Retrieved on: 
Thursday, March 23, 2023
Exercise, Indian stock exchange, NOT, TSX Venture Exchange, Section 50C of the Isle of Man Income Tax Act 1970, FOR, Tax, Foreign Investment in Real Property Tax Act, Underwriting, Sale, Initial public offering, Offering, Charity, Income Tax Act, Common, Security (finance), Closing

VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Tudor Gold Corp. (TSXV: TUD) (the “Company”) is pleased to announce that it has entered into an agreement with Research Capital Corporation, as the lead underwriter and sole bookrunner (the “Lead Underwriter”), on behalf of a syndicate of underwriters (collectively, the “Underwriters”), whereby the Underwriters will purchase, on a bought-deal basis, securities of the Company (the “Offered Securities”) for aggregate gross proceeds to the Company of approximately $10,000,000 (the “Offering”) in a combination of:

Key Points: 
  • The Offered Securities to be issued under the Offering will be offered by way of private placement in each of the provinces of Canada.
  • The Offered Securities and securities underlying the Compensation Warrants (as defined herein) to be issued under the Offering will have a hold period of four months and one day from Closing.
  • The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S.
  • This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.